Cara Therapeutics, Inc. (CARA)

1,0200 -0,0400 (-3,77%) Börsenschluss: 04:00PM EST

Cara Therapeutics, Inc.

4 Stamford Plaza
9th Floor 107 Elm Street
Stamford, CT 06902
United States
203 406 3700
https://www.caratherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 106

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christopher A. Posner	President, CEO & Director	1,2M	N/A	1970
Mr. Ryan D. Maynard	Chief Financial Officer	511,7k	N/A	1969
Dr. Joana Goncalves M.D.	Chief Medical Officer	747,25k	N/A	1974
Dr. Derek T. Chalmers D.Sc., Ph.D.	Co-Founder & Senior Advisor	580,93k	N/A	1964
Dr. Frédérique Menzaghi	Chief Scientific Officer and Senior VP of R&D	826,94k	N/A	1966
Dr. Iris Francesconi Ph.D.	Chief Strategy Officer & Head of Investor Relations	N/A	N/A	N/A
Mr. Scott M. Terrillion	Chief Compliance Officer, General Counsel & Corporate Secretary	689,63k	N/A	1963
Mr. Eric Vandal	Senior Vice President of Commercial	N/A	N/A	N/A
Ms. Beth Weinberg R.Ph.	Senior Vice President of Regulatory Affairs & QA	N/A	N/A	N/A
Mr. Matthew Murphy	Manager of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

Corporate Governance

Cara Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Dezember 2023, lautet 6. Die grundlegenden Scores sind Audit: 4, Vorstand: 4, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.